The development of an experimental system that contains these immune cells, as well as tumor cells, to better reflect the true complexity of the tumor microenvironment will be key to further delineating the mechanism of IL-10 in regulating ICI immunotherapy. The gene discussed is IL10; the disease is neoplasm.